MOTS-c has become a fixture in longevity-focused conversations. What benefits does the published literature actually support, and why is there no standardized human dosage to quote?
What we know from the literature
MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome, first characterized as a regulator of metabolic homeostasis that activates AMPK signaling under metabolic stress (Lee et al., Cell Metab, 2015, PMID 25738459). In that founding study, MOTS-c administration prevented age-dependent and diet-induced insulin resistance and reduced diet-induced obesity in mice. A comprehensive 2023 review summarizes MOTS-c’s broader role across stress adaptation, energy metabolism, and aging biology, and notes that circulating MOTS-c levels decline with age in humans (J Transl Med, 2023, PMID 36670507). Outcomes are individual, and this evidence base remains weighted heavily toward animal models rather than large human trials.
What "benefits" actually means here
The metabolic benefits described in the literature, improved insulin sensitivity, reduced diet-induced obesity, favorable shifts in plasma metabolic markers, come primarily from mouse studies and in vitro human-cell work, not large controlled human clinical trials (Kim et al., Physiol Rep, 2019, PMID 31293078). That is a meaningfully different evidence tier than a completed human efficacy trial. Outcomes are individual, and it would be inaccurate to present mouse-model findings as an established human benefit; the honest framing is that MOTS-c represents a genuinely promising area of mitochondrial signaling literature that has not yet been fully validated in people.
Why we won’t publish a MOTS-c dosage here
The ranges reported in the published literature describe doses administered to mice in specific metabolic studies; no standardized, validated human dosing protocol has been established for MOTS-c. A US-licensed provider will individualize any prescription based on your evaluation, taking into account your health history and goals, rather than a figure drawn from a mouse study designed for an entirely different purpose. Not medical advice: publishing a specific number here would overstate what the current evidence supports. Individual results vary, and that is precisely why dosing is a clinical decision rather than a number pulled from an animal study.
How to access it responsibly
- Everything is available after a licensed-provider evaluation.
- Peptides are compounded through a US-licensed compounding pharmacy.
Sources
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. doi:10.1016/j.cmet.2015.02.009. PMID 25738459 pubmed.ncbi.nlm.nih.gov/25738459/
- Reynolds JC et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21(1):36. PMID 36670507 pubmed.ncbi.nlm.nih.gov/36670507/
- Kim SJ et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. PMID 31293078 pubmed.ncbi.nlm.nih.gov/31293078/